Skip to content

Effect of AN-PEP enzyme on the effects of gluten ingestion in patients with coeliac disease

Effect of AN-PEP enzyme on the effects of gluten ingestion in patients with coeliac disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26422
Enrollment
14
Registered
2008-04-18
Start date
2008-05-05
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac disease patients

Interventions

Patients will consume 8 g wheat protein daily with AN-PEP enzyme for 14 d. After a 14-d washout period, patients who are negative for coeliac disease symptoms during the 1st period will randomly recei

Sponsors

DSM Food Specialties
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of coeliac disease (Marsh III B/C) ; that means crypt hyperplasia and subtotal or total villous atrophy, while using a normal diet followed by normalisation and clinical improvement on a gluten-free diet. 2. Detectable coeliac disease specific antibodies (EMA, tTGA) at time of diagnosis. 3. A strict gluten free diet for at least 1 year and normalised villous architecture (Marsh 0/I). 4. Male and female, 18-70 years old. 5. No detectable anti-endomysium and low anti-tissue transglutaminase (<4 U/ml) prior to the start of the study. 6. Patient is willing to undergo all protocol related assessments and visits (including up to 3 separate oesophago-gastro-duodenoscopies with multiple biopsies taken each time from the descending duodenum. 7. Patient has read the information provided on the study and given written consent; 8. Female participants at fertile age must use adequate contraception.

Exclusion criteria

Exclusion criteria: 1. Use of any immunoregulatory drug within the last 6 months 2. Use of any anticoagulant drug 3. Clinically suspected bleeding tendency 4. Pregnancy or breast feeding 5. Presence of any concurrent active infection 6. IgA deficiency 7. Use of medication within 8 hour prior to intervention

Design outcomes

Primary

MeasureTime frame
Immunohistopathological changes in small intestinal biopsies to diagnose coeliac disease

Secondary

MeasureTime frame
- Gluten reactive T cells - Coeliac disease specific antibodies - Coeliac disease-associated clinical symptoms (questionnaire) to diagnose coeliac disease

Contacts

Public ContactC.J. Mulder

Department of Gastroenterology VUmc, Amsterdam P.O. Box 7057,

cjmulder@vumc.nl+31 (0)20 4440613

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)